PMID- 38226907
OWN - NLM
STAT- MEDLINE
DCOM- 20250624
LR  - 20250624
IS  - 2724-6116 (Electronic)
IS  - 2724-6116 (Linking)
VI  - 50
IP  - 2
DP  - 2025 Jun
TI  - Association between circulating betatrophin levels and T2DM: a meta-analysis.
PG  - 201-208
LID - 10.23736/S2724-6507.23.04073-3 [doi]
AB  - INTRODUCTION: The association between betatrophin level and type 2 diabetes 
      mellitus (T2DM) is a subject of controversy, and the reasons for conflicting 
      results have been poorly explained. To address this gap, we conducted a 
      meta-analysis of relevant studies to obtain a more comprehensive estimate and 
      draw a more accurate conclusion. EVIDENCE ACQUISITION: This study included 
      literature published up to June 2023. We searched for relevant studies in the Web 
      of Science and PubMed databases. We utilized STATA 12.0 software to calculate the 
      standard mean difference (SMD) and 95% confidence interval (CI) to compare 
      circulating betatrophin levels between individuals with T2DM and healthy controls 
      (HCs). EVIDENCE SYNTHESIS: The meta-analysis revealed a significantly higher 
      circulating betatrophin level in individuals with T2DM compared to HC, using a 
      random effects model [mean value of betatrophin level (T2DM vs. HC): 388,685.23 
      vs. 304,857.04 pg/mL; SMD=1.37; 95%CI: 1.01, 1.73]. Subgroup analysis indicated a 
      higher circulating betatrophin level in T2DM compared to HC among Asian 
      individuals, while no significant difference in circulating betatrophin level was 
      observed between T2DM and HC among Caucasian individuals (Asian: SMD=1.65; 95%CI: 
      1.23, 2.06; Caucasian: SMD=0.50; 95%CI: -0.21, 1.20). Additionally, subgroup 
      analysis revealed increased plasma and serum betatrophin levels in T2DM compared 
      to HC (plasma: SMD=1.30; 95%CI: 0.72, 1.88; serum: SMD=1.47; 95%CI: 0.98, 1.96). 
      CONCLUSIONS: This meta-analysis provides evidence of elevated levels of 
      betatrophin in individuals with T2DM, suggesting that betatrophin may serve as a 
      potential diagnostic biomarker for T2DM.
FAU - Zhan, Yuquan
AU  - Zhan Y
AD  - Department of Endocrinology, Jinan Third People's Hospital, Jinan, China - 
      hjsl12ddlsls@outlook.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20240116
PL  - Italy
TA  - Minerva Endocrinol (Torino)
JT  - Minerva endocrinology
JID - 101777342
RN  - 0 (Angiopoietin-Like Protein 8)
RN  - 0 (ANGPTL8 protein, human)
RN  - 0 (Angiopoietin-like Proteins)
RN  - 0 (Peptide Hormones)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/blood
MH  - Angiopoietin-Like Protein 8/blood
MH  - *Angiopoietin-like Proteins/blood
MH  - *Peptide Hormones/blood
EDAT- 2024/01/16 13:42
MHDA- 2025/06/24 11:10
CRDT- 2024/01/16 10:12
PHST- 2025/06/24 11:10 [medline]
PHST- 2024/01/16 13:42 [pubmed]
PHST- 2024/01/16 10:12 [entrez]
AID - S2724-6507.23.04073-3 [pii]
AID - 10.23736/S2724-6507.23.04073-3 [doi]
PST - ppublish
SO  - Minerva Endocrinol (Torino). 2025 Jun;50(2):201-208. doi: 
      10.23736/S2724-6507.23.04073-3. Epub 2024 Jan 16.